Ultragenyx Pharmaceutical...
(RARE) ✕
AI Score
Our AI model analyzes fundamental, technical, and statistical indicators
to predict the probability of a bullish trend over the next three months.
We regularly update and refine our models to deliver the most reliable forecasts
for you.
Bullish Probability | Sentiment | Score |
---|---|---|
+80% | Strong Buy | 10 |
+75% | Buy | 9 |
+70% | Buy | 8 |
+60% | Buy | 7 |
+50% | Hold | 6 |
+45% | Hold | 5 |
+40% | Hold | 4 |
+35% | Sell | 3 |
+30% | Sell | 2 |
+20% | Strong Sell | 1 |
undefined
undefined%
At close: undefined
41.20
-0.72%
After-hours Jan 03, 2025, 04:07 PM EST
Income Statement (Annual)
Get detailed income statement breakdowns, uncovering revenue, expenses, and much more.
Year | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 | FY11 |
Revenue | 434.25M | 363.33M | 351.41M | 271.03M | 103.71M | 51.49M | 2.61M | 133.00K | n/a | n/a | n/a | n/a | n/a |
Cost of Revenue | 45.21M | 28.32M | 16.01M | 6.13M | 9.01M | 1.15M | 1K | 183.20M | 1.38M | n/a | n/a | n/a | n/a |
Gross Profit | 389.04M | 335.01M | 335.40M | 264.90M | 94.71M | 50.35M | 2.61M | -183.07M | -1.38M | n/a | n/a | n/a | n/a |
Operating Income | -569.21M | -648.92M | -381.74M | -330.12M | -424.17M | -371.37M | -328.94M | -248.01M | -147.74M | -56.78M | -32.28M | -15.98M | -6.56M |
Interest Income | 26.69M | 11.07M | 1.93M | 7.04M | 13.24M | 9.54M | 4.07M | 3.79M | 2.32M | 608.00K | 216.00K | 1K | 4.00K |
Pretax Income | -608.46M | -701.73M | -452.98M | -185.36M | -399.44M | -197.10M | -318.34M | -245.84M | -145.62M | -59.80M | -35.07M | -16.33M | -6.85M |
Net Income | -606.64M | -707.42M | -454.02M | -186.57M | -402.73M | -197.61M | -302.14M | -245.87M | -145.62M | -59.80M | -35.07M | -16.33M | -6.85M |
Selling & General & Admin | 309.80M | 278.14M | 219.98M | 182.93M | 161.52M | 127.72M | 99.91M | 64.94M | 33.00M | 10.81M | 4.45M | 3.34M | 1.84M |
Research & Development | 648.45M | 705.79M | 497.15M | 412.08M | 357.36M | 294.00M | 231.64M | 183.20M | 114.74M | 45.97M | 27.83M | 12.64M | 4.72M |
Other Expenses | n/a | 9.51M | 241.00K | 7.64M | 12.45M | 3.95M | 10.60M | 2.17M | -200.00K | -3.02M | -3.01M | -350.00K | -22.00K |
Operating Expenses | 958.25M | 983.93M | 717.13M | 595.02M | 518.88M | 421.72M | 331.55M | 248.14M | 147.74M | 56.78M | 32.28M | 15.98M | 6.56M |
Interest Expense | 66.00M | 43.02M | 29.42M | 33.29M | 1.14M | n/a | n/a | n/a | n/a | n/a | n/a | n/a | 270.00K |
Selling & Marketing Expenses | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Cost & Expenses | 1.00B | 1.01B | 733.14M | 601.15M | 527.89M | 422.87M | 331.55M | 248.14M | 147.74M | 56.78M | 32.28M | 15.98M | 6.56M |
Income Tax | -1.82M | 5.70M | 1.04M | 1.21M | 3.28M | 514.00K | -16.20M | 35.00K | -2.32M | -684.00K | -3.01M | -350.00K | 248.00K |
Shares Outstanding (Basic) | 73.54M | 69.91M | 67.80M | 60.85M | 56.58M | 49.78M | 42.45M | 39.59M | 36.78M | 28.76M | 29.06M | 23.06M | 23.06M |
Shares Outstanding (Diluted) | 73.54M | 69.91M | 67.80M | 60.85M | 56.58M | 49.78M | 42.45M | 39.59M | 36.78M | 28.76M | 29.06M | 23.06M | 23.06M |
EPS (Basic) | -8.25 | -10.12 | -6.7 | -3.07 | -7.12 | -3.97 | -7.12 | -6.21 | -3.96 | -2.08 | -1.21 | -0.71 | -0.3 |
EPS (Diluted) | -8.25 | -10.12 | -6.7 | -3.07 | -7.12 | -3.97 | -7.12 | -6.21 | -3.96 | -2.08 | -1.21 | -0.71 | -0.3 |
EBITDA | -516.45M | -640.51M | -410.32M | -139.81M | -389.77M | -177.56M | -312.51M | -244.58M | -146.35M | -56.09M | -34.63M | -16.02M | -6.54M |
Depreciation & Amortization | 26.01M | 18.20M | 13.24M | 12.26M | 8.54M | 19.54M | 5.83M | 3.42M | 1.38M | 684.00K | 444.00K | 313.00K | 34.00K |